By studying fifty COVID-19 patients, researchers in France identified a unique signature - a combination of deficiency in a response of a particular interferon, as well as exacerbated inflammation - in the most critically ill. They propose this signature, which may be a hallmark of severe COVID-19, provides a rationale for therapeutic approaches that combine interferon supplementation with neutralization of inflammatory signaling.
COVID-19 is characterized by distinct patterns of disease progression depending on the patient, which implies patients exhibit different immune responses to the SARS-Cov-2 virus. So far, studies suggest some 5-10% of patients progress to severe or critical disease. However, little is known about the immunological features involved in COVID-19 severity.
To help to fill this gap, the researchers analyzed immune cells of COVID-19 patients with symptoms ranging from mild to critical. The critical patients exhibited a distinctive dual signature involving a deficiency in responses of type I interferons, proteins that help fight viral infections, as well as exacerbated proinflammatory signaling.
While recent work to investigate the role of interferon signaling in COVID-19 patients has shown that local interferon signaling may be important to mitigate disease progression, the results of this dtudy suggest broader production of interferons may in fact be beneficial.
The work of these studies collectively reinforces a growing hypothesis that the location, timing, and duration of interferon exposure are critical parameters underlying the success of therapeutics for SARS-CoV-2 infections. The authors. also suggest severely ill COVID-19 patients could be treated with a combined approach focused on interferon administration and adapted anti-inflammatory therapies, "a hypothesis worth cautious testing," they say.
https://science.sciencemag.org/content/early/2020/07/10/science.abc6027
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fimpaired-type-i&filter=22
Severe COVID-19 patients had impaired type I interferon activity and inflammatory responses
- 1,400 views
- Added
Edited
Latest News
DNA attached to nanoparticl…
By newseditor
Posted 29 Mar
Neighboring synapses shape…
By newseditor
Posted 29 Mar
Complete vascularization of…
By newseditor
Posted 28 Mar
Immune cells identified as…
By newseditor
Posted 28 Mar
TB blood test which could d…
By newseditor
Posted 27 Mar
Other Top Stories
AI can detect pneumonia in COVID-19 patients from CT scan
Read more
Bacterium Linked to Deadly Childhood Hydrocephalus Discovered!
Read more
Feeding C-section newborns with maternal fecal bacteria restores gu…
Read more
Gut microbe transcription suppressed by invading virus
Read more
Multiple sclerosis drug inhibits coronavirus in the lab studies
Read more
Protocols
Spatial proteomics in neuro…
By newseditor
Posted 28 Mar
All-optical presynaptic pla…
By newseditor
Posted 23 Mar
Epigenomic tomography for p…
By newseditor
Posted 20 Mar
A mouse DRG genetic toolkit…
By newseditor
Posted 17 Mar
An optogenetic method for t…
By newseditor
Posted 13 Mar
Publications
DNA corona on nanoparticles…
By newseditor
Posted 29 Mar
Co-dependent excitatory and…
By newseditor
Posted 29 Mar
A microfluidic platform int…
By newseditor
Posted 28 Mar
Salmonella manipulates macr…
By newseditor
Posted 28 Mar
BHLHE40/41 regulate microgl…
By newseditor
Posted 28 Mar
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar